Case Report

A 41-Year-Old HIV-Positive Man with Acute Onset of Quadriplegia after West Nile Virus Infection

Authors: Suzanna Connick Jamison, MD, MSN, Sarah R. Michaels, MSPH, Raoult Ratard, MPH, MD, MS, FACPM, Jon M. Sweet, MD, FACP, Bennett P. deBoisblanc, MD, FACP, FCCP, FCCM

Abstract

Most cases of West Nile encephalitis virus (WNV) infection are asymptomatic. In cases where WNV is symptomatic, patients usually experience high fever of sudden onset, myalgia, headache, and gastrointestinal symptoms, accompanied by a macular erythematous rash in a quarter to half of cases. More severe infections manifest as a poliomyelitis. Immunocompromise and immune senescence confer an increased risk of severe central nervous system (CNS) infection. Patients with human immunodeficiency virus (HIV) infection are therefore more susceptible, but, because the symptoms of WNV infection may be attributed to other CNS syndromes common in HIV patients, it is likely that the presence of WNV infection is underdiagnosed and underreported. We present a patient with severe WNV infection who was found to be HIV positive, who also suffered hearing loss. Several key differences in the presentation of WNV infection and Guillain-Barré syndrome that have treatment implications are discussed.


Key Points


* West Nile Virus poliomyelitis syndrome most often presents with asymmetric muscle weakness, in contrast to Guillain-Barré, which presents with ascending paralysis and sensory symptoms.


* CSF analysis can help differentiate among West Nile Virus infection, bacterial meningitis, and Guillain-Barré.


* West Nile Virus infection may be underdiagnosed in the immunocompromised and elderly, whose debility may be attributed to their general clinical condition.


* Diagnosis of acute West Nile Virus infection requires detection of WNV IgM antibodies in acute and convalescent serum samples, or a single acute cerebrospinal fluid (CSF) sample, or by demonstrating a 4-fold rise in WNV IgG titer between acute and convalescent sera.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Campbell GL, Marfin AA, Lanciotti RS, et al. West Nile virus. Lancet Infect Dis 2002;2:519–529.
 
2. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999: results of a household-based seroepidemiological survey. Lancet 2001;358:261–264.
 
3. Sejvar JJ, Leis AA, Stokic DS, et al. Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis 2003;9:788–793.
 
4. Miller AH, Liang IE. Diplopia: a focal neurologic presentation of West Nile. Ann Emerg Med 2003;42:413–416.
 
5. Thomson RB, Bertram H. Laboratory diagnosis of central nervous system infections. In: Cockerill FR (ed). Infectious Disease Clinics of North America; The Role of the Clinical Microbiology Laboratory in the Diagnosis and Therapy of Infectious Disease. W.B. Saunders, Philadelphia, 2001, pp 1047–1071.
 
6. Lowry PW. Arbovirus encephalitis in the United States and Asia. J Lab Clin Med 1997;129:405–411.
 
7. Pepperell C, Rau N, Krajden S, et al. West Nile virus infection in 2002: morbidity and mortality among patients admitted to a hospital in south central Ontario. CMAJ 2003;168:1399–1405.
 
8. Hayes CG. West Nile virus: Uganda, 1937, to New York City, 1999. Ann N Y Acad Sci, 2001;951:25–37.
 
9. Camenga DL, Nathanson N, Cole GA. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis 1974;130:634–641.
 
10. Diamond MS, Shrestha B, Marri A, et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003;77:2578–2586.
 
11. Jeha LE, Sila CA, Lederman RJ, et al. West Nile virus infection: a new acute paralytic illness. Neurology 2003;61:55–59.
 
12. Kulstad EB, Wichter MD. West Nile encephalitis presenting as a stroke. Ann Emerg Med 2003;41:283.
 
13. Nichter CA, Pavlakis SG, Shaikh U, et al. Rhombencephalitis caused by West Nile fever virus. Neurology 2000;55:153.
 
14. Gadoth N, Weitzman S, Lehmann EE. Acute anterior myelitis complicating West Nile fever. Arch Neurol 1979;36:172–173.
 
15. Brinton MA. Host factors involved in West Nile virus replication. Ann N Y Acad Sci 2001;951:207–219.
 
16. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus. JAMA 2003;290:511–515.
 
17. Ahmed S, Libman R, Wesson K, et al. Guillain-Barre syndrome: an unusual presentation of West Nile. Neurology 2000;55:144–146.
 
18. Leis AA, Stokic DS, Polk JL, et al. A poliomyelitis-like syndrome from West Nile virus infection. N Engl J Med 2002;347:1279–1280.
 
19. Sitati EM, Diamond MS. CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system J Virol 2006;80:12060–12069.
 
20. Savarino A, Boelart JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003;3:722–727.